Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ukraine Adopts USTR Action Plan To Improve IP Protection For Gateway To Commonwealth Of Independent States

This article was originally published in PharmAsia News

Executive Summary

Ukraine has agreed to adopt an action plan to strengthen the country's intellectual property regime to draw foreign investment to the second-largest emerging market in the Commonwealth of Independent States, after Russia

You may also be interested in...



Russia Signs MOU With U.S. Pharmacopeia To Improve Drug Quality

The Russian Ministry of Healthcare and Social Development (Minzdravsoc) and the U.S. Pharmacopeia Convention signed a memorandum of understanding to improve the quality of medicines in the Russian Federation

Russia Signs MOU With U.S. Pharmacopeia To Improve Drug Quality

The Russian Ministry of Healthcare and Social Development (Minzdravsoc) and the U.S. Pharmacopeia Convention signed a memorandum of understanding to improve the quality of medicines in the Russian Federation

Astellas Splits Sales Emerging Growth In Russia And China, But A Late Entry To India May Soon Be Rewarded

TOKYO - Japanese firm Astellas seems content pursuing emerging market growth on its own, perhaps eschewing partnering activity like its main Japanese competitors to expand in its newest markets in the BRIC countries - Brazil, Russia, India and China

Latest News
See All
UsernamePublicRestriction

Register

SC077544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel